Treatment
- TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b.
- TUB-040 is given IV every 3 weeks, combined with carboplatin (max. 6 cycles) and bevacizumab
Treatment duration
The treatment can continue until disease progression, unacceptable toxicity or withdrawal of consent.
Eligibility
Main inclusion criteria:
- Platinum-sensitive ovarian cancer (max. 2 prior lines)
- Measurable disease by RECIST 1.1
- Archival tissue available for determination of biomarker (eg. NaPi2b) expression
Main exclusion criteria:
- Has a history of non-infectious ILD/pneumonitis/radiation pneumonitis that required steroids or has current ILD/pneumonitis.
Disclaimer: This is an overview of the main in- and exclusion criteria. Criteria might change during the course of the study due to amendments. Inclusion in the trial remains the responsibility of the principal investigator of the trial and will depend on patient eligibility and slot availability.
Contact
In case you feel your patient might be eligible for this trial or in case you want to have more information about this trial, please feel free to contact us via: lgog@uzleuven.be